Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 2/2001

01-05-2001 | ORIGINAL ARTICLE

Expression of L-selectin and efficient binding to high endothelial venules do not modulate the dissemination potential of murine B-cell lymphoma

Authors: Ronit Aviram, Nava Raz, Tova Kukulansky, Nurit Hollander

Published in: Cancer Immunology, Immunotherapy | Issue 2/2001

Login to get access
Metadata
Title
Expression of L-selectin and efficient binding to high endothelial venules do not modulate the dissemination potential of murine B-cell lymphoma
Authors
Ronit Aviram
Nava Raz
Tova Kukulansky
Nurit Hollander
Publication date
01-05-2001
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 2/2001
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/PL00006682

Other articles of this Issue 2/2001

Cancer Immunology, Immunotherapy 2/2001 Go to the issue

ORIGINAL ARTICLE

Generation of human anti-MUC3 IgG antibodies after in vitro immunization of naive peripheral blood B-lymphocytes

ORIGINAL ARTICLE

Human scFv antibody fragments specific for the epithelial tumour marker MUC-1, selected by phage display on living cells

ORIGINAL ARTICLE

Tributyrin enhances the cytotoxic activity of interleukin-2/interleukin-12 stimulated human natural killer cells against LS 174T colon cancer cells in vitro

ORIGINAL ARTICLE

Relationship between tumour morphology, antigen and antibody distribution measured by fusion of digital phosphor and photographic images

ORIGINAL ARTICLE

Long-term treatment with low doses of interleukin-2 and interferon-α: immunological effects in advanced renal cell cancer

ORIGINAL ARTICLE

Targeting properties of an anti-CD16/anti-CD30 bispecific antibody in an in vivo system
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits